Chiron Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Chiron Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$249K	Buy	+1,947	New	+$243K	0.25%	99
2025 Q3	$7.12M	Sell	71,084 -8,254	-10%	-$743K	6.1%	2
2025 Q2	$6.58M	Sell	79,338 -4,557	-5%	-$364K	5.72%	2
2025 Q1	$6.8M	Sell	83,895 -3,307	-4%	-$296K	6.18%	2
2024 Q4	$7.85M	Sell	87,202 -1,703	-2%	-$165K	7.41%	2
2024 Q3	$8.78M	Sell	88,905 -2,449	-3%	-$241K	7.77%	2
2024 Q2	$8.47M	Sell	91,354 -718	-0.8%	-$64.4K	8.09%	2
2024 Q1	$8.74M	Sell	92,072 -48,517	-35%	-$4.5M	7.94%	2
2023 Q4	$12.6M	Sell	140,589 -8,117	-5%	-$603K	10.92%	2
2023 Q3	$10.9M	Buy	148,706 +10,496	+8%	+$838K	9.34%	2
2023 Q2	$11.5M	Sell	138,210 -29,100	-17%	-$2.43M	9.11%	2
2023 Q1	$12.8M	Buy	167,310 +17,883	+12%	+$1.48M	8.86%	2
2022 Q4	$12.4M	Sell	149,427 -8,871	-6%	-$718K	8.63%	2
2022 Q3	$12.6M	Sell	158,298 -8,528	-5%	-$719K	8.44%	2
2022 Q2	$12.4M	Buy	166,826 +8,619	+5%	+$647K	7.82%	2
2022 Q1	$14.2M	Buy	158,207 +112,928	+249%	+$10.4M	8.96%	2
2021 Q4	$5.07M	Buy	45,279 +5,753	+15%	+$694K	3.66%	3
2021 Q3	$4.97M	Buy	39,526 +31,015	+364%	+$3.99M	3.62%	4
2021 Q2	$1.15M	Buy	8,511 +5,692	+202%	+$748K	0.96%	24
2021 Q1	$382K	Buy	2,819 +507	+22%	+$75.9K	0.32%	52
2020 Q4	$325K	Sell	2,312 -1,680	-42%	-$215K	0.27%	60
2020 Q3	$445K	Buy	+3,992	New	+$448K	0.36%	42

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Chiron Capital Management's XBI Position: Q1 2026 in Review

Chiron Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 1,947 shares worth $249K. The stake represents 0.25% of the portfolio and ranks #99 among its holdings. This is a return to the name: Chiron Capital Management previously reported a position in XBI as recently as Q3 2025.

Chiron Capital Management first reported a position in XBI in Q3 2020 and has held it in 22 quarters since. The position peaked at $14.2M in Q1 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Chiron Capital Management held 1,947 shares of State Street SPDR S&P Biotech ETF worth $249K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new Chiron Capital Management position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.25% of Chiron Capital Management's portfolio in Q1 2026, its #99 holding.
Chiron Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 22 quarters since.
Chiron Capital Management's State Street SPDR S&P Biotech ETF position peaked at $14.2M in Q1 2022.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Chiron Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.